-99.9%
DFNS vs MRNA
+27.9%
-127.8%
-100.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.5% | +0.7% | +0.8% | +1.6% |
| 7D | -3.3% | -8.2% | +4.9% | -3.6% |
| 30D | -73.1% | +125.6% | -198.7% | -71.1% |
| 3M | -71.4% | +197.1% | -268.4% | -67.7% |
| 6M | -93.8% | +148.5% | -242.3% | -93.4% |
| YTD | -98.0% | +363.3% | -461.3% | -97.4% |
| 1Y | -98.2% | +462.0% | -560.2% | -97.4% |
| All | -99.9% | +27.9% | -127.8% | -99.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling